Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Long-Term Debt Issuances (2022)

Historic Long-Term Debt Issuances for UroGen Pharma (URGN) over the last 1 years, with Q4 2022 value amounting to $25.0 million.

  • UroGen Pharma's Long-Term Debt Issuances changed N/A to $25.0 million in Q4 2022 from the same period last year, while for Sep 2023 it was $25.0 million, marking a year-over-year decrease of 6469.99%. This contributed to the annual value of $24.5 million for FY2024, which is N/A changed from last year.
  • Per UroGen Pharma's latest filing, its Long-Term Debt Issuances stood at $25.0 million for Q4 2022.
  • UroGen Pharma's Long-Term Debt Issuances' 5-year high stood at $70.8 million during Q1 2022, with a 5-year trough of -$38000.0 in Q2 2022.